

DAFTAR PUSTAKA

6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. (2024). *Diabetes Care*, 48(Supplement_1), S128–S145. <https://doi.org/10.2337/dc25-S006>
- Abu-Nejem, R., & Hannon, T. S. (2024). Insulin Dynamics and Pathophysiology in Youth-Onset Type 2 Diabetes. In *Journal of Clinical Endocrinology and Metabolism* (Vol. 109, Issue 10, pp. 2411–2421). Endocrine Society. <https://doi.org/10.1210/clinem/dgae463>
- Advani, A. (2020). Positioning time in range in diabetes management. *Diabetologia*, 63(2), 242–252. <https://doi.org/10.1007/s00125-019-05027-0>
- American Diabetes Association Professional Practice Committee. (2023). Standards of Care in Diabetes—2023. *Diabetes Care*, 46(Suppl. 1) Amin, S., Saraswati, E., Ayu, D., Ilhami, D., Muliadi, P., Anggraeni, Y. D., Pratama, A., Studi, P., Farmasi, S., Farmasi, F., Baktif, U., & Husada, T. (2025). MEKANISME KERJA OBAT ANTI DIABETES GOLONGAN BIGUANID DAN SULFONILUREA TINJAUAN KIMIA MEDISINAL. NERS. <http://journal.universitaspahlawan.ac.id/index.php/ners>.
- Anastasiou, G., Liberopoulos, E., Tentolouris, N., & Papanas, N. (2024). Diabetic Sensorimotor Polyneuropathy: An Overview on Epidemiology, Risk Factors, Classification, Diagnosis, and Treatment. *The International Journal of Lower Extremity Wounds*, 15347346241240512. <https://doi.org/10.1177/15347346241240513>
- Anggriani, Y., Rianti, A., Pratiwi, A. N., & Puspitasari, W. (2020). Evaluasi Penggunaan Insulin pada Pasien Diabetes mellitus tipe 2 Rawat Jalan di Rumah Sakit X di Jakarta Periode 2016-2017. *Jurnal Sains Farmasi & Klinis*, 7(1), 52. <https://doi.org/10.25077/jsfk.7.1.52-59.2020>.
- Bala, D. F. S., Aditya, M., & Cesa, F. Y. (2023). Evaluasi penggunaan obat antidiabetes pada pasien Diabetes Mellitus tipe 2 di Rumah Sakit Baptis Batu. *Sainsbertek Jurnal Ilmiah Sains & Teknologi*, 3(2), 9–18
- Brereton, M. F., Rohm, M., Shimomura, K., Holland, C., Tornovsky-Babeay, S., Dadon, D., Iberl, M., Chibalina, M. V., Lee, S., Glaser, B., Dor, Y., Rorsman, P., Clark, A., & Ashcroft, F. M. (2016). Hyperglycaemia induces metabolic

- dysfunction and glycogen accumulation in pancreatic β -cells. *Nature Communications*, 7. <https://doi.org/10.1038/ncomms13496>
- Care, D., & Suppl, S. S. (2024). Introduction and Methodology: Standards of Care in Diabetes — 2024. 47(January), 1–4.
- Ceriello, A., & Inagaki, N. (2017). Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. *Journal of Diabetes Investigation*, 8(1), 19–28. <https://doi.org/10.1111/jdi.12528>
- Dave, H. D., & Preuss, C. V. (2023). Human Insulin. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK545190/> Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. Metformin pathways: Pharmacokinetics and pharmacodynamics. *Pharmacogenetics and Genomics*, 22(11), 820–827. <https://doi.org/10.1097/FPC.0b013e328359b22>
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B. (2022). Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 45(11), 2753–2786. <https://doi.org/10.2337/dci22-0034>
- Đekić, D., Bojić, M., Janež, A., Klobučar, S., Hadžimušović, I. G., Ković, T., & Mihalevska, S. (2023). Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study. *Diabetes Therapy*, 14(7), 1217–1229. <https://doi.org/10.1007/s13300-023-01407-3>
- Dyah Rahadini, A. A., Murtini, S., & Soehita, S. (2023). INSULIN THERAPY IN T2DM PATIENTS IN DIABETES OUTPATIENT CLINIC, DR. SOETOMO GENERAL ACADEMIC HOSPITAL, SURABAYA, INDONESIA. *Majalah Biomorfologi*, 33(1), 38–43. <https://doi.org/10.20473/mbiom.v33i1.2023.38-43>

- Elsayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. Lou, Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A. (2023). 6. Glycemic Targets: Standards of Care in Diabetes—2023. *Diabetes Care*, 46, S97–S110. <https://doi.org/10.2337/dc23-S006>
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Kosiborod, M., Leon, J., Lyons, S. K., ... Association, on behalf of the A. D. (2022). Introduction and Methodology: Standards of Care in Diabetes—2023. *Diabetes Care*, 46(Supplement_1), S1–S4. <https://doi.org/10.2337/dc23-Sint>
- Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN TIPE, P. (n.d.). PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELLITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.
- Guan, H., Tian, J., Wang, Y., Niu, P., Zhang, Y., Zhang, Y., Fang, X., Miao, R., Yin, R., & Tong, X. (2024). Advances in secondary prevention mechanisms of macrovascular complications in type 2 diabetes mellitus patients: a comprehensive review. *European Journal of Medical Research*, 29(1), 1–34. <https://doi.org/10.1186/s40001-024-01739-1>
- Heri Suroso, Iswati, & Renza Luthfia. (2024). Asuhan Keperawatan Pada Pasien Diabetes Mellitus Dengan Masalah Keperawatan Defisit Pengetahuan Bahaya Hipoglikemia.
- International Diabetes Federation. (2021). *IDF Diabetes Atlas (10th ed.)*
- International Diabetes Federation. (2023). *International Diabetes Federation Annual Report*. <https://idf.org/>
- International Diabetes Federation. (2024). *International Diabetes Federation Annual Report*.
- International Diabetes Federation. (2025). *IDF Diabetes Atlas (11th ed.)* Janez, A., Muzurovic, E., Bonski, P., Czupryniak, L., Fabryova, L., Fras, Z., Guja, C.,

- Haluzik, M., Kempler, P., Lalic, N., Mullerova, D., Stoian, A. P., Papanas, N., Rahelic, D., Silva-Nunes, J., Tankova, T., Yumuk, V., & Rizzo, M. (2024). Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group. *Diabetes Therapy*, 15(9), 1865–1892. <https://doi.org/10.1007/s13300-024-01615-5>
- Jayaprakash, L. (2024). Microvascular and Macrovascular Complications of Type 2 Diabetes. www.JSR.org/hs
- Kasina, S. V. S. K., & Baradhi, K. M. (2023). Dipeptidyl Peptidase IV (DPP IV) Inhibitors. *Dipeptidyl Peptidase IV (DPP IV) Inhibitors*, 1–5. <https://www.ncbi.nlm.nih.gov/books/NBK542331/>
- Kementerian Kesehatan Republik Indonesia. (2019). Pedoman Pelayanan Kefarmasian pada Diabetes Mellitus.
- Kemenkes RI. (2021). PROFIL KESEHATAN INDONESIA.
- Kementerian Kesehatan Republik Indonesia. (2018). Laporan nasional Riset Kesehatan Dasar (Riskesdas).
- Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Kaabi, J. Al. (2020). Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. *Journal of Epidemiology and Global Health*, 10(1), 107–111. <https://doi.org/10.2991/JEGH.K.191028.001>
- Kim, N., & Song, Y. (2026). Measurement Properties of Instruments Used to Assess Diabetic Foot: An Umbrella Review. <https://doi.org/10.1155/jdr/3322840>
- Kusumawati, N. N., & Andayani, T. M. (2024). Review: Cost-Effectiveness Analysis Metformin dan Dipeptidyl Peptidase-4 Inhibitor Dibandingkan dengan Metformin dan Sulfonilurea pada Pasien Diabetes mellitus tipe 2. *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, 9(2), 325. <https://doi.org/10.20961/jpscr.v9i2.91911>
- Lingvay, I., Sumithran, P., Cohen, R. V, & le Roux, C. W. (2022). Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *The Lancet*, 399(10322), 394–405. [https://doi.org/10.1016/S0140-6736\(21\)01919-X](https://doi.org/10.1016/S0140-6736(21)01919-X)

- Made, N., Arini, A., Made, I., & Dwipayana, P. (n.d.). HUBUNGAN KADAR HbA1c TERHADAP TERAPI OBAT ANTI DIABETES ORAL DAN KOMBINASI OBAT ANTI DIABETES ORAL-INSULIN PADA PENDERITA DM TIPE 2 DI POLIKLINIK DIABETES RSUP SANGLAH DENPASAR TAHUN 2016. <https://doi.org/10.24843.MU.2020.V9.i9.P16>.
- Marassi, M., & Fadini, G. P. (2023). The cardio - renal - metabolic connection: a review of the evidence. *Cardiovascular Diabetology*, 1–12. <https://doi.org/10.1186/s12933-023-01937-x>
- Marcianò, G., Vocca, C., Casarella, A., Gallelli, L., Rania, V., De Sarro, C., Citraro, R., Palleria, C., Bianco, R. C., Fera, I., Greco, A., Muraca, L., Nanci, G., Rossi, C. L., Ashour, M., D'Agostino, B., & De Sarro, G. (2024). The Prescription and Safety of Oral Antidiabetic Drugs in Outpatients with Type 2 Diabetes Mellitus: An Observational, Retrospective, Multicenter Study on the Role of Adherence in a Real-Life Primary Care Setting. *Diabetology*, 5(3), 333–343. <https://doi.org/10.3390/diabetology5030025>
- McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024). The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review. *Diabetes Therapy*, 15(5), 1085–1098. <https://doi.org/10.1007/s13300-024-01569-8>
- Melichova, J., Sivco, P., Rusnak, M., Phuong Truc, P., & Majdan, M. (2023). International evidence-based guidelines on hypertension and type 2 diabetes mellitus: A systematic review. *Journal of Public Health Research*, 12(1). <https://doi.org/10.1177/22799036221146913>
- Milner, Z., & Akhondi, H. (2023). Repaglinide. *XPharm: The Comprehensive Pharmacology Reference*, 1–3. <https://doi.org/10.1016/B978-008055232-3.62525-5>
- Mudaliar, S., & Henry, R. R. (2023). Thiazolidinediones. *Type 2 Diabetes: Principles and Practice*, Second Edition, 137–158. <https://doi.org/10.3109/9780849379581-14>
- Nur Rosyidah, N., Studi Kebidanan, P., Tinggi Ilmu Kesehatan Dian Husada Mojokerto, S., Agus Cahyono, E., Studi Keperawatan, P., & Keperawatan

- Dian Husada Mojokerto, A. (2025). DIABETES MELLITUS TIPE 2 ; ARTIKEL REVIEW. 3.
- Pedoman Nasional Pelayanan Kedokteran (PNPK) Tata Laksana Diabetes mellitus tipe 2 Dewasa. (2020). Kementerian Kesehatan Republik Indonesia, 1–183.
- PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELLITUS TIPE 2 DI INDONESIA 2024 PERKUMPULAN ENDOKRINOLOGI INDONESIA. (2024).
- PERKENI. (2021a). PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELLITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.
- PERKENI. (2021b). PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELLITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.
- PERKENI. (2024a). Pengelolaan dan Pencegahan Diabetes mellitus tipe 2 Dewasa di Indonesia 2024 (PERKENI, Ed.).
- Powers, D. B., Breeze, J., & Erdmann diabetes mellitus tipe 2 ann, D. (2022). Vascularized Fibula TMJ Reconstruction: A Report of Five Cases featuring Computerized Patient-specific Surgical Planning. Plastic and Reconstructive Surgery. Global Open, 10(8), e4465. <https://doi.org/10.1097/GOX.0000000000004465>
- Rozzini, R. (2019). The geriatric canon. Monaldi Archives for Chest Disease, 89(1), 45–51. <https://doi.org/10.4081/monaldi.2019.1028>.
- Sunarti. (2021). Daun pucuk merah: Inovasi dan pengembangan obat herbal sebagai terapi antidiabetes. Malang: Literasi Nusantara Abadi. Arifin, B., Idrus, L. R., van Asselt, A. D. I., Purba, F. D., Perwitasari, D. A., Thobari, J. A., Cao, Q., Krabbe, P. F. M., & Postma, M. J. (2019). Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D. Quality of Life Research, 28(5), 1179–1190. <https://doi.org/10.1007/s11136-019-02105-z>.
- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., & Williams, R. (2019). Global and regional diabetes prevalence

- estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, 157. <https://doi.org/10.1016/j.diabres.2019.107843>
- Soeatmadji, D. W., Rosandi, R., Saraswati, M. R., Sibarani, R. P., & Tarigan, W. O. (2023). Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of DISCOVER: A 3-Year Prospective Cohort Study. *Journal of the ASEAN Federation of Endocrine Societies*, 38(1), 68–74. <https://doi.org/10.15605/jafes.038.01.10>
- Standards-of-Medical-Care-in-Diabetes-2020_ADA. (n.d.).
- Studi Diploma III Keperawatan, P., Keperawatan, J., & Kemenkes Palangka Raya, P. (n.d.). LITERATUR REVIEW: GULA DARAH PUASA PADA PENYAKIT DIABETES MELLITUS Baharuddin Yusuf, Syahida Nafisah, Novianti Nuril Inayah. In *Pharmacy Medical Journal* (Vol. 6, Issue 1).
- Sukirawati, S. (2025). Tinjauan Efek Samping Penggunaan Metformin Pada Pasien Diabetes Mellitus Tipe Ii Di Apotek Kimia Farma Alauddin Bulan Juli-Desember 2023. *Jurnal Kesehatan Yamasi Makassar*, 9(1), 48–55. <https://doi.org/10.59060/jurkes.v9i1.375>
- Suprapti, B., Izzah, Z., Anjani, A. G., Andarsari, M. R., Nilamsari, W. P., & Nugroho, C. W. (2023). Prevalence of medication adherence and glycemic kontrol among patients with type 2 diabetes and influencing factors: A cross-sectional study. *Global Epidemiology*, 5, 100113. <https://doi.org/10.1016/j.gloepi.2023.100113>
- Usui, I. (2023). Common metabolic features of hypertension and type 2 diabetes. *Hypertension Research*, 46(5), 1227–1233. <https://doi.org/10.1038/s41440-023-01233-x>
- Utami, Y. T. (2018). PENGARUH KARAKTERISTIK PASIEN TERHADAP KUALITAS PELAYANAN RAWAT JALAN DI UPTD PUSKESMAS PENUMPING SURAKARTA. In *INFOKES* (Vol. 8, Issue 1).
- Valencia Andreani, F., Belladonna, M., & Hendrianingtyas, M. (2018). HUBUNGAN ANTARA GULA DARAH SEWAKTU DAN PUASA

DENGAN PERUBAHAN SKOR NIHSS PADA STROKE ISKEMIK AKUT. 7(1), 185–198.

Vieira, R., Souto, S. B., Sánchez-López, E., Machado, A. L., Severino, P., Jose, S., Santini, A., Fortuna, A., García, M. L., Silva, A. M., & Souto, E. B. (2019). Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—review of classical and new compounds: Part-i. In *Pharmaceuticals* (Vol. 12, Issue 4). MDPI AG. <https://doi.org/10.3390/ph12040152>

WHO discussion group for people living with diabetes. (2023).

WHO. (2020). Guidance on global monitoring for diabetes prevention and control Framework, indicators and application.

Widiasari, K. R., Made, I., Wijaya, K., & Suputra, P. A. (2021). TATALAKSANA. In *Ganesha Medicina Journal* (Vol. 1).

Wu, Q., Zhang, J., Zhang, F., & Li, D. (2025). SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes. In *Frontiers in Endocrinology* (Vol. 16). Frontiers Media SA. <https://doi.org/10.3389/fendo.2025.160163>

Zaim, M., Purwastyastuti, P., & Nafrialdi, N. (2021). Analisis Efektivitas Insulin Analog dan Human yang Digunakan pada Penderita Diabetes Mellitus Tipe-2 dengan Biaya BPJS di RS. Islam Sukapura 2018. *Muhammadiyah Journal of Geriatric*, 2(1), 17. <https://doi.org/10.24853/mujg.2.1.17-26>

Zdziechowski, A., Zdziechowska, M., Rysz, J., & Woldańska-Okońska, M. (2024). The Effectiveness of Preoperative Outpatient and Home Rehabilitation and the Impact on the Results of Hip Arthroplasty: Introductory Report. *Healthcare* (Switzerland), 12(3). <https://doi.org/10.3390/healthcare12030327>

Zubirán, R., Cruz-Bautista, I., & Aguilar-Salinas, C. A. (2024). Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications. *Diabetes Therapy*, 15(9), 1979–2000. <https://doi.org/10.1007/s13300-024-01626-2>